All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Powering insights from Cortellis. Link to Cortellis page on Clarivate website.
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing the state of COVID-19 testing
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 16, 2021
Home » Topics » Series B, BioWorld

Series B, BioWorld
%{topic} RSS Feed RSS

3D Euro symbol

IO Biotech fuels immuno-oncology resurgence with $155M series B round

Last updated: Jan. 13, 2021
By Cormac Sheridan
No Comments
Dublin – IO Biotech ApS raised €127 million (US$154.7 million) in a series B round to fund a potentially pivotal trial of its combination of cancer vaccines in first-line metastatic melanoma. The Copenhagen, Denmark-based company is one of a number of firms fueling a mini-resurgence in immuno-oncology in the early weeks of the new year, as new data and new insights are prompting additional investments in an area that some had thought was already oversubscribed.
Read More
Business, data, dollars illustration

Tessera raises $230M series B to advance gene writing tech

Last updated: Jan. 13, 2021
By Michael Fitzhugh
No Comments
Tessera Therapeutics Inc., a Cambridge, Mass.-based company working to "write therapeutic instructions into the genome," has raised $230 million in series B financing to back its development of potential cures and treatments for cardiovascular, oncological, neurodegenerative and infectious diseases.
Read More
Gary Glick, CEO and co-founder, Scorpion

The sting: Scorpion brings in an oversubscribed $162M series B

Last updated: Jan. 7, 2021
By Lee Landenberger
No Comments
In less than a year, Scorpion Therapeutics Inc. has raised about $270 million and just closed on an oversubscribed series B financing that climbed to $162 million. The new financing quickly follows the Boston-based company’s founding at the end of the first quarter of 2020 and the closure of a $108 million series A financing in October.
Read More
3D dollar sign

Immuneering secures $62M series B to advance tech-driven pipeline

Last updated: Jan. 6, 2021
By Michael Fitzhugh
No Comments
Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own medicines, has landed $62 million in an oversubscribed series B financing that will help it leverage lessons learned in that journey to build out its own pipeline, starting with IMM-1-104, a dual inhibitor of MEK and a related target.
Read More
Pregnancy

Minervax closes $58M series B round for group B strep vaccine

Last updated: Dec. 15, 2020
By Cormac Sheridan
No Comments
DUBLIN – Minervax Aps raised €47.4 million (US$57.6 million) in a series B funding round to take a recombinant-protein-based vaccine for group B streptococcus (GBS) through a phase II program as well as parallel surveillance studies to enable it to define correlates of protection against GBS in newly born infants.
Read More

A second ‘rayze’: Rayzebio closes $105M series B for preclinical radiopharmaceutical pipeline

Last updated: Jan. 13, 2021
By Cormac Sheridan
No Comments
Rayzebio Inc. has swiftly followed up its recent $45 million series A round with a $105 million series B round that attracted several top-tier crossover investors.
Read More
Gastrointestinal-microbiome

AI microbiome firm Xbiome raises $20M+ to push candidates into clinic

Last updated: Dec. 1, 2020
By Elise Mak
No Comments
Shenzhen Xbiome Biotech Co. Ltd., an artificial intelligence (AI)-based microbiome drugmaker, raised more than $20 million in a series B+ round, Xbiome CEO Yan Tan told BioWorld, financing that will help the company launch its phase I trial next year. It has been a year since the drugmaker closed a $14 million series B round. During this period, Tan said Xbiome submitted an IND to the FDA in October for its fecal microbiota transplant (FMT) capsule candidate, a potential treatment for graft-vs.-host disease.
Read More

Catalym closes $59M series B round for GDF-15 inhibitor

Last updated: Nov. 10, 2020
By Cormac Sheridan
No Comments
DUBLIN – Catalym GmbH pressed the accelerator on its growth differentiation factor 15 (GDF-15) inhibitor program by raising €50 million (US$59 million) in series B financing, which will fund a first-in-human study lined up to start before year-end.
Read More
Antibodies attacking SARS-CoV-2 virus

Memo trains convalescent antibody on COVID-19

Last updated: Nov. 9, 2020
By Cormac Sheridan
No Comments
DUBLIN – Memo Therapeutics AG raised CHF13.8 million (US$15.3 million) in a first close of a series B round to take forward a patient-derived monoclonal antibody therapy for COVID-19, MTX-Covab, which will move into a phase I/II trial in Germany in the new year.
Read More
CD47 protein structure

Immuneonco bags $25M in series B for CD47 antibodies development

Last updated: Oct. 23, 2020
By Gina Lee
No Comments
HONG KONG – Shanghai, China-based Immuneonco Biopharmaceuticals Co. Ltd. bagged $25 million in series B financing in October. The funding will mainly support the companies’ immunotherapies, which include IMM-01 and IMM-0306, both of which target CD47.
Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • British flag

    Accuracy, utility of COVID-19 lateral flow tests questioned in the U.K.

    BioWorld MedTech
    LONDON – A huge row has broken out in the U.K. about the accuracy and utility of COVID-19 lateral flow tests (LFT) in screening asymptomatic people, as a pilot...
  • Total artificial heart being manufactured

    Carmat's artificial heart receives CE mark

    BioWorld MedTech
    Carmat SA said its total artificial heart received the CE mark, and the company plans to ramp up production to enable the launch of the device in the second...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 15.
  • Israeli flag

    Israel continues to shine as hub of med-tech innovation

    BioWorld MedTech
    In recent years, Israel has proven to be a hot spot for med-tech innovation. The country boasts more than 1,500 companies in the health care and life sciences...
  • Doctor examining child in wheelchair

    Sarepta DMD phase II hangs in ‘balance’ as disparity in North Star leads astray

    BioWorld
    Sarepta Therapeutics Inc.’s miss on a key phase II ambulatory endpoint in its Duchenne muscular dystrophy (DMD) trial may have been caused by a dramatic disparity...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing